The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Related articles in The JI
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Moroz, A.
Right arrow Articles by Shrikant, P. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moroz, A.
Right arrow Articles by Shrikant, P. A.
The Journal of Immunology, 2004, 173: 900-909.
Copyright © 2004 by The American Association of Immunologists

IL-21 Enhances and Sustains CD8+ T Cell Responses to Achieve Durable Tumor Immunity: Comparative Evaluation of IL-2, IL-15, and IL-211

Adrianna Moroz*, Cheryl Eppolito*, Qingsheng Li*, Jianming Tao*, Christopher H. Clegg{dagger} and Protul A. Shrikant2,*

* Department of Immunology, Roswell Park Cancer Institute, Buffalo, NY 14263; and {dagger} Department of Immunology, Zymogenetics, Seattle, WA 98102

Cytokines that use the common receptor {gamma}-chain for regulating CD8+ T cell responses to Ag include IL-2, IL-15, and the recently identified IL-21. The ability of these cytokines to regulate antitumor activity in mice has generated considerable interest in understanding their mode of action. In this study we compare the abilities of IL-2, IL-15, and IL-21 to stimulate immunity against tumors in a syngeneic thymoma model. Durable cures were only achieved in IL-21-treated mice. By monitoring both endogenous and adoptively transferred tumor Ag-specific CD8+ T cells, it was determined that IL-21 activities overlap with those of IL-2 and IL-15. Similar to IL-2, IL-21 enhanced Ag activation and clonal expansion. However, unlike IL-2 treatment, which induces activation-induced cell death, IL-21 sustained CD8+ T cell numbers long term as a result of increased survival, an effect often attributed to IL-15. These findings indicate that the mechanisms used by IL-21 to promote CD8+ T cell responses offer unique opportunities for its use in malignant diseases and infections.


Related articles in The JI:

IN THIS ISSUE

The JI 2004 173: 713-714. [Full Text]  



This article has been cited by other articles:


Home page
J. Immunol.Home page
H. Sondergaard, J. M. Coquet, A. P. Uldrich, N. McLaughlin, D. I. Godfrey, P. V. Sivakumar, K. Skak, and M. J. Smyth
Endogenous IL-21 Restricts CD8+ T Cell Expansion and Is not Required for Tumor Immunity
J. Immunol., December 1, 2009; 183(11): 7326 - 7336.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
A. E. Hogg, G. C. Bowick, N. K. Herzog, M. W. Cloyd, and J. J. Endsley
Induction of granulysin in CD8+ T cells by IL-21 and IL-15 is suppressed by human immunodeficiency virus-1
J. Leukoc. Biol., November 1, 2009; 86(5): 1191 - 1203.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. Thedrez, C. Harly, A. Morice, S. Salot, M. Bonneville, and E. Scotet
IL-21-Mediated Potentiation of Antitumor Cytolytic and Proinflammatory Responses of Human V{gamma}9V{delta}2 T Cells for Adoptive Immunotherapy
J. Immunol., March 15, 2009; 182(6): 3423 - 3431.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
R. Spolski, H.-P. Kim, W. Zhu, D. E. Levy, and W. J. Leonard
IL-21 Mediates Suppressive Effects via Its Induction of IL-10
J. Immunol., March 1, 2009; 182(5): 2859 - 2867.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
K. Castermans, S. P. Tabruyn, R. Zeng, J. R. van Beijnum, C. Eppolito, W. J. Leonard, P. A. Shrikant, and A. W. Griffioen
Angiostatic activity of the antitumor cytokine interleukin-21
Blood, December 15, 2008; 112(13): 4940 - 4947.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. L. Kinter, E. J. Godbout, J. P. McNally, I. Sereti, G. A. Roby, M. A. O'Shea, and A. S. Fauci
The Common {gamma}-Chain Cytokines IL-2, IL-7, IL-15, and IL-21 Induce the Expression of Programmed Death-1 and Its Ligands
J. Immunol., November 15, 2008; 181(10): 6738 - 6746.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
T. Y. Wuest, J. Willette-Brown, S. K. Durum, and A. A. Hurwitz
The influence of IL-2 family cytokines on activation and function of naturally occurring regulatory T cells
J. Leukoc. Biol., October 1, 2008; 84(4): 973 - 980.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. Ansen, M. O. Butler, A. Berezovskaya, A. P. Murray, K. Stevenson, L. M. Nadler, and N. Hirano
Dissociation of Its Opposing Immunologic Effects Is Critical for the Optimization of Antitumor CD8+ T-Cell Responses Induced by Interleukin 21
Clin. Cancer Res., October 1, 2008; 14(19): 6125 - 6136.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. Kasprzycka, Q. Zhang, A. Witkiewicz, M. Marzec, M. Potoczek, X. Liu, H. Y. Wang, M. Milone, S. Basu, J. Mauger, et al.
{gamma}c-Signaling Cytokines Induce a Regulatory T Cell Phenotype in Malignant CD4+ T Lymphocytes
J. Immunol., August 15, 2008; 181(4): 2506 - 2512.
[Abstract] [Full Text] [PDF]


Home page
Int ImmunolHome page
S. Ferrari-Lacraz, R. Chicheportiche, G. Schneiter, N. Molnarfi, J. Villard, and J.-M. Dayer
IL-21 promotes survival and maintains a naive phenotype in human CD4+ T lymphocytes
Int. Immunol., August 1, 2008; 20(8): 1009 - 1018.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
R. Halwani, J. D. Boyer, B. Yassine-Diab, E. K. Haddad, T. M. Robinson, S. Kumar, R. Parkinson, L. Wu, M. K. Sidhu, R. Phillipson-Weiner, et al.
Therapeutic Vaccination with Simian Immunodeficiency Virus (SIV)-DNA+IL-12 or IL-15 Induces Distinct CD8 Memory Subsets in SIV-Infected Macaques
J. Immunol., June 15, 2008; 180(12): 7969 - 7979.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
T. Iuchi, S. Teitz-Tennenbaum, J. Huang, B. G. Redman, S. D. Hughes, M. Li, G. Jiang, A. E. Chang, and Q. Li
Interleukin-21 Augments the Efficacy of T-Cell Therapy by Eliciting Concurrent Cellular and Humoral Responses
Cancer Res., June 1, 2008; 68(11): 4431 - 4441.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
J. A. Thompson, B. D. Curti, B. G. Redman, S. Bhatia, J. S. Weber, S. S. Agarwala, E. L. Sievers, S. D. Hughes, T. A. DeVries, and D. F. Hausman
Phase I Study of Recombinant Interleukin-21 in Patients With Metastatic Melanoma and Renal Cell Carcinoma
J. Clin. Oncol., April 20, 2008; 26(12): 2034 - 2039.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. J. Smyth, M. W.L. Teng, J. Sharkey, J. A. Westwood, N. M. Haynes, H. Yagita, K. Takeda, P. V. Sivakumar, and M. H. Kershaw
Interleukin 21 Enhances Antibody-Mediated Tumor Rejection
Cancer Res., April 15, 2008; 68(8): 3019 - 3025.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. Marzec, K. Halasa, M. Kasprzycka, M. Wysocka, X. Liu, J. W. Tobias, D. Baldwin, Q. Zhang, N. Odum, A. H. Rook, et al.
Differential Effects of Interleukin-2 and Interleukin-15 versus Interleukin-21 on CD4+ Cutaneous T-Cell Lymphoma Cells
Cancer Res., February 15, 2008; 68(4): 1083 - 1091.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
I. D. Davis, K. Skak, M. J. Smyth, P. E.G. Kristjansen, D. M. Miller, and P. V. Sivakumar
Interleukin-21 Signaling: Functions in Cancer and Autoimmunity
Clin. Cancer Res., December 1, 2007; 13(23): 6926 - 6932.
[Abstract] [Full Text] [PDF]


Home page
Int ImmunolHome page
S. Liu, G. Lizee, Y. Lou, C. Liu, W. W. Overwijk, G. Wang, and P. Hwu
IL-21 synergizes with IL-7 to augment expansion and anti-tumor function of cytotoxic T cells
Int. Immunol., October 1, 2007; 19(10): 1213 - 1221.
[Abstract] [Full Text] [PDF]


Home page
Int ImmunolHome page
T. Onoda, M. Rahman, H. Nara, A. Araki, K. Makabe, K. Tsumoto, I. Kumagai, T. Kudo, N. Ishii, N. Tanaka, et al.
Human CD4+ central and effector memory T cells produce IL-21: effect on cytokine-driven proliferation of CD4+ T cell subsets
Int. Immunol., October 1, 2007; 19(10): 1191 - 1199.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
B. R. Barker, J. G. Parvani, D. Meyer, A. S. Hey, K. Skak, and N. L. Letvin
IL-21 Induces Apoptosis of Antigen-Specific CD8+ T Lymphocytes
J. Immunol., September 15, 2007; 179(6): 3596 - 3603.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
V. Ostiguy, E.-L. Allard, M. Marquis, J. Leignadier, and N. Labrecque
IL-21 promotes T lymphocyte survival by activating the phosphatidylinositol-3 kinase signaling cascade
J. Leukoc. Biol., September 1, 2007; 82(3): 645 - 656.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
K. A. Casey and M. F. Mescher
IL-21 Promotes Differentiation of Naive CD8 T Cells to a Unique Effector Phenotype
J. Immunol., June 15, 2007; 178(12): 7640 - 7648.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
I. D. Davis, B. K. Skrumsager, J. Cebon, T. Nicholaou, J. W. Barlow, N. P. H. Moller, K. Skak, D. Lundsgaard, K. S. Frederiksen, P. Thygesen, et al.
An Open-Label, Two-Arm, Phase I Trial of Recombinant Human Interleukin-21 in Patients with Metastatic Melanoma
Clin. Cancer Res., June 15, 2007; 13(12): 3630 - 3636.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
L. White, S. Krishnan, N. Strbo, H. Liu, M. A. Kolber, M. G. Lichtenheld, R. N. Pahwa, and S. Pahwa
Differential effects of IL-21 and IL-15 on perforin expression, lysosomal degranulation, and proliferation in CD8 T cells of patients with human immunodeficiency virus-1 (HIV)
Blood, May 1, 2007; 109(9): 3873 - 3880.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
D. Herber, T. P. Brown, S. Liang, D. A. Young, M. Collins, and K. Dunussi-Joannopoulos
IL-21 Has a Pathogenic Role in a Lupus-Prone Mouse Model and Its Blockade with IL-21R.Fc Reduces Disease Progression
J. Immunol., March 15, 2007; 178(6): 3822 - 3830.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. Cappuccio, M. Elishmereni, and Z. Agur
Cancer immunotherapy by interleukin-21: potential treatment strategies evaluated in a mathematical model.
Cancer Res., July 15, 2006; 66(14): 7293 - 7300.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
J. M. Roda, R. Parihar, A. Lehman, A. Mani, S. Tridandapani, and W. E. Carson III
Interleukin-21 Enhances NK Cell Activation in Response to Antibody-Coated Targets
J. Immunol., July 1, 2006; 177(1): 120 - 129.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
E. Bolesta, A. Kowalczyk, A. Wierzbicki, C. Eppolito, Y. Kaneko, M. Takiguchi, L. Stamatatos, P. A. Shrikant, and D. Kozbor
Increased Level and Longevity of Protective Immune Responses Induced by DNA Vaccine Expressing the HIV-1 Env Glycoprotein when Combined with IL-21 and IL-15 Gene Delivery
J. Immunol., July 1, 2006; 177(1): 177 - 191.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. J. Smyth, Y. Hayakawa, E. Cretney, N. Zerafa, P. Sivakumar, H. Yagita, and K. Takeda
IL-21 Enhances Tumor-Specific CTL Induction by Anti-DR5 Antibody Therapy
J. Immunol., May 15, 2006; 176(10): 6347 - 6355.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
D. de Totero, R. Meazza, S. Zupo, G. Cutrona, S. Matis, M. Colombo, E. Balleari, I. Pierri, M. Fabbi, M. Capaia, et al.
Interleukin-21 receptor (IL-21R) is up-regulated by CD40 triggering and mediates proapoptotic signals in chronic lymphocytic leukemia B cells
Blood, May 1, 2006; 107(9): 3708 - 3715.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. J. Burgess, A. I. Marusina, I. Pathmanathan, F. Borrego, and J. E. Coligan
IL-21 Down-Regulates NKG2D/DAP10 Expression on Human NK and CD8+ T Cells
J. Immunol., February 1, 2006; 176(3): 1490 - 1497.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. Comes, O. Rosso, A. M. Orengo, E. Di Carlo, C. Sorrentino, R. Meazza, T. Piazza, B. Valzasina, P. Nanni, M. P. Colombo, et al.
CD25+ Regulatory T Cell Depletion Augments Immunotherapy of Micrometastases by an IL-21-Secreting Cellular Vaccine
J. Immunol., February 1, 2006; 176(3): 1750 - 1758.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
L.-X. Wang, R. Li, G. Yang, M. Lim, A. O'Hara, Y. Chu, B. A. Fox, N. P. Restifo, W. J. Urba, and H.-M. Hu
Interleukin-7-Dependent Expansion and Persistence of Melanoma-Specific T Cells in Lymphodepleted Mice Lead to Tumor Regression and Editing
Cancer Res., November 15, 2005; 65(22): 10569 - 10577.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
R. Takaki, Y. Hayakawa, A. Nelson, P. V. Sivakumar, S. Hughes, M. J. Smyth, and L. L. Lanier
IL-21 Enhances Tumor Rejection through a NKG2D-Dependent Mechanism
J. Immunol., August 15, 2005; 175(4): 2167 - 2173.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
Y. Li, M. Bleakley, and C. Yee
IL-21 Influences the Frequency, Phenotype, and Affinity of the Antigen-Specific CD8 T Cell Response
J. Immunol., August 15, 2005; 175(4): 2261 - 2269.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
N. L. Alves, F. A. Arosa, and R. A. W. van Lier
IL-21 Sustains CD28 Expression on IL-15-Activated Human Naive CD8+ T Cells
J. Immunol., July 15, 2005; 175(2): 755 - 762.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2004 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2004 by The American Association of Immunologists, Inc. All rights reserved.